PMID- 12139206
OWN - NLM
STAT- MEDLINE
DCOM- 20030108
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 40
IP  - 7
DP  - 2002 Jul
TI  - Trospium chloride in patients with detrusor overactivity: meta-analysis of 
      placebo-controlled, randomized, double-blind, multi-center clinical trials on the 
      efficacy and safety of 20 mg trospium chloride twice daily.
PG  - 295-303
AB  - OBJECTIVES: Primary objective of this meta-analysis was to produce a systematic 
      and quantitative review of two independent clinical trials of 20 mg trospium 
      chloride (TCI) twice daily (b.i.d.) in patients with detrusor overactivity 
      [Alloussi et al. 1998, Cardozo et al. 2000]. PATIENTS AND METHODS: In two 
      placebo-controlled, double-blind, multi-center studies, the effect of TCl on 
      detrusor function was evaluated using urodynamic measurements. All 517 patients 
      were randomized to receive TCl or placebo for 3 weeks. Urodynamic variables were 
      measured at the beginning and at the end of the treatment. Safety was evaluated 
      on the basis of adverse events (AEs), vital signs and laboratory tests. RESULTS: 
      TCl produced significant improvements in 'maximum cystometric bladder capacity' 
      (median treatment effect = 52 ml, 95% confidence interval 32-71 ml, p<0.0001) and 
      'urinary volume at first unstable contraction' (median treatment effect = 48 ml, 
      95% confidence interval 28 to 68 ml, p = 0.0001). The patients' assessment of 
      efficacy also showed significantly greater clinical improvement in the TCl group 
      than in the placebo group (p < 0.0001). The patients recorded a 'cure' or a 
      'marked improvement' more often in the TCl group than in the placebo group (47.9% 
      and 19.7%, respectively). TCl was well tolerated, with similar frequencies of AEs 
      reported in both groups (TCl: 35.7%, placebo group: 38.9%). CONCLUSIONS: Trospium 
      chloride (20 mg twice daily) is an effective and safe medication for the 
      treatment of detrusor overactivity.
FAU - Frohlich, G
AU  - Frohlich G
AD  - CRMB GmbH, Rheinbach, Germany. gfroehl@tin.it
FAU - Bulitta, M
AU  - Bulitta M
FAU - Strosser, W
AU  - Strosser W
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Benzilates)
RN  - 0 (Nortropanes)
RN  - 0 (Parasympatholytics)
RN  - 1E6682427E (trospium chloride)
SB  - IM
MH  - Benzilates
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nortropanes/administration & dosage/adverse effects/*pharmacology
MH  - Parasympatholytics/administration & dosage/adverse effects/*pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Urinary Bladder, Neurogenic/*drug therapy/physiopathology
MH  - Urodynamics/drug effects
EDAT- 2002/07/26 10:00
MHDA- 2003/01/09 04:00
CRDT- 2002/07/26 10:00
PHST- 2002/07/26 10:00 [pubmed]
PHST- 2003/01/09 04:00 [medline]
PHST- 2002/07/26 10:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2002 Jul;40(7):295-303.